Sharekhan's research report on Hindustan Unilever Limited
The GSK Group sold 5.7% stake (13.37 crore shares) in Hindustan Unilever (HUL) through multiple block deals in the open market. This has reduced the supply overhang in the stock. The merger of GSK Consumer Healthcare's business with HUL will make the latter one of the largest players in the domestic foods space and would lead to earnings accretion of 4-8% over FY2021/FY2022. HUL’s stock price has corrected by ~16% from its recent high factors in the sluggish performance in Q4FY2020. With 50-55% of business catering to essential categories and the company’s strong direct distribution reach, we expect HUL to recover rapidly post the pandemic situation.
Outlook
HUL has a strong balance sheet with robust cash flows and goods dividend payout which makes it a safest bet in the uncertain environment. We maintain our Buy recommendation on the stock with unchanged PT of Rs. 2,305.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.